Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 116 clinical trials
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.

  • 58 views
  • 09 Jun, 2021
  • 191 locations
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder

bladder cancer
gemcitabine
bladder tumor
invasive bladder cancer
cancer
  • 76 views
  • 22 Jun, 2021
  • 105 locations
Urine-based Detection of Non-muscle Invasive Bladder

Non-muscle invasive bladder cancer (NMIBC), which comprises approximately 75% of bladder tumors, has the highest recurrence rate of all cancers, with around 70% of the patients developing local

bladder cancer
cystoscopy
bladder tumor
invasive bladder cancer
cancer
  • 0 views
  • 24 Jan, 2021
  • 1 location
  • 95 views
  • 20 Jun, 2021
  • 194 locations
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gu rin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

bladder cancer (NMIBC) who harbor fibroblast growth factor receptor (FGFR) mutations or fusions, and who recurred after bacillus calmette-guerin (BCG) therapy.

bladder cancer
intravesical chemotherapy
gemcitabine
bladder tumor
invasive bladder cancer
  • 0 views
  • 21 Jun, 2021
  • 197 locations
Impact of Remimazolam on Prognosis After Bladder Cancer Surgery

Bladder cancer is one of the most common genitourinary cancers. Transurethral resection of bladder tumor (TURBT) is the standard therapy for nonmuscle invasive bladder cancer. However, patients

  • 0 views
  • 11 Apr, 2021
  • 1 location
A Study of TAR-200 in Combination With Cetrelimab TAR-200 Alone or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease.

intravesical bcg
cystoscopy
bladder tumor
invasive bladder cancer
carcinoma
  • 0 views
  • 28 May, 2021
  • 175 locations
Celecoxib With Chemotherapy in Localized Muscle-Invasive Bladder Cancer

The purpose of this study is to compare patient tumor tissue before and after treatment with chemotherapy plus celecoxib. Investigators will look at gene expression, to see what effect celecoxib may have on tumor cells.

hydronephrosis
cystoscopy
bladder carcinoma
cancer
metastasis
  • 10 views
  • 20 Jun, 2021
  • 2 locations
Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

This study will enrol patients with maximally resected (via transurethral resection (TURBT) non-metastatic muscle invasive bladder cancer, who either wish to attempt bladder preservation therapy

anticoagulants
aptt
cystoscopy
bladder carcinoma
cancer
  • 39 views
  • 30 Jan, 2021
  • 8 locations
Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer

Research Hypothesis Approximately 75% of patients with bladder cancer (BC) present with a disease confined to the mucosa (stage Ta, CIS) or submucosa (stage T1) (non-muscle invasive BC [NMIBC]). For high grade NMIBC, i.e. TaG3, T1G3 and CIS, intravesical bacillus Calmette-Gurin (BCG) immunotherapy is the treatment of choice, given that …

bladder cancer
intravesical administration
neutrophil count
bladder tumor
invasive bladder cancer
  • 14 views
  • 26 Jan, 2021
  • 1 location